Nuvation Bio (Nuvation Bio) Debt-to-Asset : 0.00 (As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Debt-to-Asset?

Nuvation Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.00 Mil. Nuvation Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.00 Mil. Nuvation Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2021 was $797.79 Mil. Nuvation Bio's debt to asset for the quarter that ended in Sep. 2021 was 0.00.

Nuvation Bio Debt-to-Asset Historical Data

The historical data trend for Nuvation Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Debt-to-Asset Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Debt-to-Asset

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Nuvation Bio's Debt-to-Asset

For the Biotechnology subindustry, Nuvation Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Debt-to-Asset falls into.

Nuvation Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nuvation Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	145.004
	=	0.00

Nuvation Bio's Debt-to-Asset for the quarter that ended in Sep. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	797.791
	=	0.00

Nuvation Bio (NYSE:NUVB.WS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nuvation Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.